RVNC
Revance Therapeutics, Inc
Revance Therapeutics, Inc historical holders
total: 1
Fairfax Financial Holdings Revance Therapeutics, Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2024 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q1
Prem Watsa has been an institutional investor in Revance Therapeutics, Inc (RVNC) since 2024 Q4. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired RVNC in 2024 Q4, initially purchasing 21,158 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.
When did Prem Watsa exit their RVNC position?
Prem Watsa no longer holds Revance Therapeutics, Inc (RVNC). They sold off their entire position in 2025 Q1, closing out an investment that began in 2024 Q4.
When did Prem Watsa first invest in RVNC?
Prem Watsa first invested in Revance Therapeutics, Inc (RVNC) in 2024 Q4 at the reported quarter-end price of $3.03 per share, acquiring 21,158 shares in their initial purchase.
What is Prem Watsa's average cost basis for RVNC?
Based on historical transaction data, Prem Watsa's estimated cost basis for Revance Therapeutics, Inc (RVNC) is approximately $3.03 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $3.03
- Weighted AVG sell price:
- $3.03
RVNC transactions history by Fairfax Financial Holdings
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$3.03
|
|
-100% (-21,158)
|
-0%
|
|
2024 Q4
|
0.00%
|
21,158
|
$3.03
|
$64,109
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.